Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

Rhea-AI Summary

Apellis Pharmaceuticals (APLS) has announced it will host a conference call and webcast to discuss its fourth quarter and full year 2024 financial results on Friday, February 28, 2025, at 8:30 a.m. ET. Interested participants must pre-register to access the live call.

The company will provide a live audio webcast with accompanying slides through the 'Events and Presentations' page on their website's 'Investors and Media' section. The webcast replay will be available for 90 days after the event.

News Market Reaction – APLS

-0.22%

-0.22% Session move

In the trading session that priced this news, APLS declined 0.22%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its fourth quarter and full year 2024 financial results on Friday, February 28, 2025, at 8:30 a.m. ET.

To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for 90 days following the event.

About Apellis 
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first-ever therapy for geographic atrophy, a leading cause of blindness around the world. We believe we have only begun to unlock the potential of targeting C3 across many serious diseases. For more information, please visit http://apellis.com or follow us on Twitter and LinkedIn.

Investor Contact:
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178

FAQ

When will Apellis Pharmaceuticals (APLS) report Q4 and full year 2024 earnings?

Apellis Pharmaceuticals will report its Q4 and full year 2024 financial results on Friday, February 28, 2025, at 8:30 a.m. ET.

How can investors access Apellis Pharmaceuticals' (APLS) Q4 2024 earnings call?

Investors can access the call by pre-registering online and through a live audio webcast available on the 'Events and Presentations' page of the company's website.

How long will Apellis Pharmaceuticals' (APLS) Q4 2024 earnings webcast be available?

The webcast replay will be available for 90 days following the event.

What does Apellis Pharmaceuticals (APLS) specialize in?

Apellis is a global biopharmaceutical company that develops complement medicines, including the first therapy for geographic atrophy, focusing on targeting C3 for challenging diseases.